BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

313 related articles for article (PubMed ID: 33387037)

  • 41. Investigation of the Relationship Between Radiation Dose and Gene Mutations and Fusions in Post-Chernobyl Thyroid Cancer.
    Efanov AA; Brenner AV; Bogdanova TI; Kelly LM; Liu P; Little MP; Wald AI; Hatch M; Zurnadzy LY; Nikiforova MN; Drozdovitch V; Leeman-Neill R; Mabuchi K; Tronko MD; Chanock SJ; Nikiforov YE
    J Natl Cancer Inst; 2018 Apr; 110(4):371-378. PubMed ID: 29165687
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Impact of Mutation Density and Heterogeneity on Papillary Thyroid Cancer Clinical Features and Remission Probability.
    Colombo C; Muzza M; Proverbio MC; Tosi D; Soranna D; Pesenti C; Rossi S; Cirello V; De Leo S; Fusco N; Miozzo M; Bulfamante G; Vicentini L; Ferrero S; Zambon A; Tabano S; Fugazzola L
    Thyroid; 2019 Feb; 29(2):237-251. PubMed ID: 30501571
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Long-term vemurafenib treatment drives inhibitor resistance through a spontaneous KRAS G12D mutation in a BRAF V600E papillary thyroid carcinoma model.
    Danysh BP; Rieger EY; Sinha DK; Evers CV; Cote GJ; Cabanillas ME; Hofmann MC
    Oncotarget; 2016 May; 7(21):30907-23. PubMed ID: 27127178
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Correlation among the BRAF gene mutation status, clinicopathological features of primary tumour, and lymph node metastasizing of papillary thyroid carcinoma.
    Lukas J; Drabek J; Dudesek B; Vazan P; Stranska J; Jancik S; Mackova M; Syrucek M; Lukas D; Duskova J; Dundr P; Hintnausova B; Jiskra J
    Exp Clin Endocrinol Diabetes; 2014 May; 122(5):268-72. PubMed ID: 24839220
    [TBL] [Abstract][Full Text] [Related]  

  • 45. ANKRD26-RET - A novel gene fusion involving RET in papillary thyroid carcinoma.
    Staubitz JI; Musholt TJ; Schad A; Springer E; Lang H; Rajalingam K; Roth W; Hartmann N
    Cancer Genet; 2019 Oct; 238():10-17. PubMed ID: 31425920
    [TBL] [Abstract][Full Text] [Related]  

  • 46. [Frequency of RET/PTC rearrangement and somatic BRAF mutation in papillary thyroid cancer].
    Rumiantsev PO; Zaletaev DV; Vasil'ev EV; Saenko VA; Il'in AA; Rumiantseva UV; Abrosimov AIu; Medvedev VS
    Vopr Onkol; 2006; 52(2):145-9. PubMed ID: 17195637
    [TBL] [Abstract][Full Text] [Related]  

  • 47. BRAF mutation in papillary thyroid cancer: pathogenic role, molecular bases, and clinical implications.
    Xing M
    Endocr Rev; 2007 Dec; 28(7):742-62. PubMed ID: 17940185
    [TBL] [Abstract][Full Text] [Related]  

  • 48. KRAS G12V Mutation in Acquired Resistance to Combined BRAF and MEK Inhibition in Papillary Thyroid Cancer.
    Owen DH; Konda B; Sipos J; Liu T; Webb A; Ringel MD; Timmers CD; Shah MH
    J Natl Compr Canc Netw; 2019 May; 17(5):409-413. PubMed ID: 31085763
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Characterization of thyroid cancer driven by known and novel ALK fusions.
    Panebianco F; Nikitski AV; Nikiforova MN; Kaya C; Yip L; Condello V; Wald AI; Nikiforov YE; Chiosea SI
    Endocr Relat Cancer; 2019 Nov; 26(11):803-814. PubMed ID: 31539879
    [TBL] [Abstract][Full Text] [Related]  

  • 50. RET/PTC rearrangements and BRAF mutations in thyroid tumorigenesis.
    Ciampi R; Nikiforov YE
    Endocrinology; 2007 Mar; 148(3):936-41. PubMed ID: 16946010
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Pediatric, Adolescent, and Young Adult Thyroid Carcinoma Harbors Frequent and Diverse Targetable Genomic Alterations, Including Kinase Fusions.
    Vanden Borre P; Schrock AB; Anderson PM; Morris JC; Heilmann AM; Holmes O; Wang K; Johnson A; Waguespack SG; Ou SI; Khan S; Fung KM; Stephens PJ; Erlich RL; Miller VA; Ross JS; Ali SM
    Oncologist; 2017 Mar; 22(3):255-263. PubMed ID: 28209747
    [TBL] [Abstract][Full Text] [Related]  

  • 52. BRAF V600E Gene Mutation Is Associated With Bilateral Malignancy of Papillary Thyroid Cancer.
    Liu Z; Lv T; Xie C; Di Z
    Am J Med Sci; 2018 Aug; 356(2):130-134. PubMed ID: 30219154
    [TBL] [Abstract][Full Text] [Related]  

  • 53. A meta-analysis evaluating the relationship between B-type Raf kinase mutation and cervical lymphatic metastasis in papillary thyroid cancer.
    Ma H; Wang R; Fang J; Zhong Q; Chen X; Hou L; Feng L; Chen X; Huang Z; Zhao H
    Medicine (Baltimore); 2020 Jan; 99(5):e18917. PubMed ID: 32000400
    [TBL] [Abstract][Full Text] [Related]  

  • 54. BRAF mutation in thyroid cancer.
    Xing M
    Endocr Relat Cancer; 2005 Jun; 12(2):245-62. PubMed ID: 15947100
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Predictive Value of BRAF
    Song JY; Sun SR; Dong F; Huang T; Wu B; Zhou J
    Curr Med Sci; 2018 Oct; 38(5):785-797. PubMed ID: 30341513
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Inhibitors of Raf kinase activity block growth of thyroid cancer cells with RET/PTC or BRAF mutations in vitro and in vivo.
    Ouyang B; Knauf JA; Smith EP; Zhang L; Ramsey T; Yusuff N; Batt D; Fagin JA
    Clin Cancer Res; 2006 Mar; 12(6):1785-93. PubMed ID: 16551863
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Classical point mutations of RET, BRAF and RAS oncogenes are not shared in papillary and medullary thyroid cancer occurring simultaneously in the same gland.
    Ciampi R; Romei C; Pieruzzi L; Tacito A; Molinaro E; Agate L; Bottici V; Casella F; Ugolini C; Materazzi G; Basolo F; Elisei R
    J Endocrinol Invest; 2017 Jan; 40(1):55-62. PubMed ID: 27535135
    [TBL] [Abstract][Full Text] [Related]  

  • 58. [Molecular analysis of structural abnormalities in papillary thyroid carcinoma gene].
    Vasil'ev EV; Rumiantsev PO; Saenko VA; Il'in AA; Poliakova EIu; Nemtsova MV; Zaletaev DV
    Mol Biol (Mosk); 2004; 38(4):642-53. PubMed ID: 15456136
    [TBL] [Abstract][Full Text] [Related]  

  • 59. BRAF mutation in papillary thyroid carcinoma: predictive value for long-term prognosis and radioiodine sensitivity.
    Zoghlami A; Roussel F; Sabourin JC; Kuhn JM; Marie JP; Dehesdin D; Choussy O
    Eur Ann Otorhinolaryngol Head Neck Dis; 2014 Feb; 131(1):7-13. PubMed ID: 23845288
    [TBL] [Abstract][Full Text] [Related]  

  • 60. High prevalence of BRAF gene mutation in papillary thyroid carcinomas and thyroid tumor cell lines.
    Xu X; Quiros RM; Gattuso P; Ain KB; Prinz RA
    Cancer Res; 2003 Aug; 63(15):4561-7. PubMed ID: 12907632
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 16.